The combination therapy of sintilimab injection, albumin-bound paclitaxel, and cisplatin for stage IB–IIIB NSCLC can effectively reduce tumor marker levels, improve immune function, demonstrating favorable clinical and pathological efficacy without increasing the incidence of adverse drug reactions. Here, ALB is linked to non-small cell lung carcinoma.